Topic:

R&D

Latest Headlines

Latest Headlines

Biocon might spin out its CRO after taking it public

Indian drugmaker Biocon is on the road to taking its in-house CRO public, and the company's founder said she's considering making the company an entirely independent operation.

UCLA adopts startup cleaning system to help stop spread of superbugs via duodenoscopes

Upstart Langford IC Systems claims that it's launching the only system that meets FDA standards for reprocessed medical device cleanliness. Its first buyer is the Ronald Reagan UCLA Medical Center in Los Angeles, which reported two patient deaths and several infections earlier this year due to insufficiently disinfected duodenoscopes, which are a type of endoscope for examining the duodenum.

Study stopped early as BMS' Opdivo bests Afinitor in kidney cancer

Bristol-Myers Squibb can brag about another success with immunotherapy Opdivo. A late-stage study in advanced kidney cancer will be stopped early, after a monitoring committee flagged improved survival results for Opdivo, compared with the Novartis treatment Afinitor.

Another Alzheimer's upstart swings for a $150M IPO with a PhIII contender

On the heels of Axovant Sciences and its $315 million IPO bash, another small drugmaker is setting its sights on Wall Street with a late-stage Alzheimer's treatment and hopes of raking in more than $150 million.

NIH-backed scientists develop wireless, remote-controlled brain implant

Amid growing interest in innovative neurological devices to treat brain disorders, scientists supported by the National Institutes of Health (NIH) are developing a wireless, remote-controlled probe that could inject drugs and highlight neurons inside the brain.

Agenus bags cancer antibodies in $44M deal

Lexington, MA-based Agenus has bagged the rights to some cancer-related antibodies from Italy's Diatheva s.r.l., agreeing to fork over up to $44 million in milestones for a successful development program.

Tekmira changes its name and shuffles away from Ebola

Tekmira Pharmaceuticals is shifting focus after years of up-and-down development, planning to change its name and train its attention on hepatitis B.

Exelixis soars as a once-failed cancer drug comes through in Phase III

Exelixis notched a crucial clinical success for its top oncology prospect, meeting its goals in a kidney cancer trial and clearing the way for a lucrative FDA nod.

UPDATED: Bristol-Myers flags early success for PhIII Opdivo study in kidney cancer

Bristol-Myers Squibb flagged an early success for its Phase III Opdivo (nivolumab) study for kidney cancer, saying that an independent monitoring group concluded that its closely watched checkpoint inhibitor has beat Afinitor (everolimus) in improving overall survival for advanced patients.

Vermillion raises $18.8M to fund escalation of bioinformatics ambitions

Vermillion has tapped investors for money to fund the enhancement of its bioinformatics platform. The diagnostics and bioanalytics player pulled in a total of $18.8 million through a stock offering, a slice of which will be ploughed into biotech IT.